The Chinese medical device market may triple by 2018, partially due to high rates of tobacco consumption and a rapidly growing economy, according to a market report.
Earlier this week a company director, Frederick Moll, picked up another 5,000 shares at $24.15 each, representing the 1st insider buy on the open market since late last year.
Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer’s Lipitor lose patent protection. Biotech generic competition is on the horizon.
J&J has been doing business in China for more than 25 years, including last year’s launch of a medical device and diagnostics innovation center there.
Limerick, Pa.-based Teleflex said it inked deals to buy the EZ-Blocker pulmonary catheter technology and Axiom Technology Partners, which makes the EFx line of laparoscopic fascial closure devices.